Enrolling by invitationPHASE1, PHASE2NCT05152823
Gene Therapy for IGHMBP2-Related Diseases
Studying Spinal muscular atrophy with respiratory distress type 1
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Megan Waldrop
- Principal Investigator
- Megan Waldrop, MDNationwide Children's Hospital
- Intervention
- Gene Therapy(biological)
- Enrollment
- 10 enrolled
- Eligibility
- 14 years · All sexes
- Timeline
- 2021 – 2030
Study locations (1)
- Nationwide Children's Hospital, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05152823 on ClinicalTrials.gov